UNSPSC 51101682: Satranidazole

This classification denotes an antiprotozoal agent with the molecular formula C8H11N5O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4N7G8A6439, chemically known as 2-imidazolidinone, 1-(1-methyl-5-nitro-1h-imidazol-2-yl)-3-(methylsulfonyl)- but generally known as satranidazole, which bears US NIH Compound Identifier 41841. European Medicines Agency schedules Satranidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10459MIG.

UNSPSC 51101682 Satranidazole is a Commodity code that sits at the narrowest tier of the taxonomy; however, the recent state and local opportunities posted under this code show a fundamental mismatch between the code's nominal scope and the work actually being solicited. The code nominally describes a single pharmaceutical active ingredient, but the recent opportunities tagged with it encompass broad categories of medical supplies, naloxone products, generic pharmaceuticals, and first-aid equipment—none of which are satranidazole-specific. State and local issuing bodies soliciting under this code include county health departments, state health and human services agencies, cities, and cooperative purchasing alliances that span multiple jurisdictions. The work being procured falls into three distinct categories: emergency medical supplies and naloxone for opioid response (Seminole County, Florida); general medical and first-aid supplies for fire department rescue operations (City of Tampa); and generic multi-source pharmaceuticals and OTC products through statewide cooperative contracts (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota and Oregon).

The geographic spread shows activity across Florida, Texas, Minnesota, and Oregon, with the most recent and substantive opportunities originating from municipal and regional cooperative procurement offices rather than a single concentration. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (IFB60459723LAS, due July 26, 2023), the City of Tampa's IFB for 169 line items of medical and first-aid supplies for its Fire Department Rescue Division with an estimated contract value of $700,000 and a Small Local Business Enterprise set-aside (26P00145, due March 13, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers with proposals due March 26, 2026. The Texas Health and Human Services Commission also posted an RFI in April 2026 regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. Because satranidazole itself does not appear in any of these solicitations, the code shows little relevant recent activity for vendors specializing in that specific product.